COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Collaboration Opportunities

Collaboration Opportunities for Antibody Characterization

In efforts to provide an open data platform for affinity reagents, NCI’s Antibody Characterization Program seeks collaboration with interesting parties to accelerate the uptake of proteomic antibody reagents and technologies in a rigorous fashion to enable basic and clinical studies, and its translation into patient care.  NCI’s Antibody Characterization Program utilizes Material Cooperative Research and Development Agreements (M-CRADAs) through Leidos Biomedical Research so that commercial vendors can use the antibody characterization pipeline.  The antibody characterization pipeline includes standardized characterization assays such as: SDS-PAGE, Western Blot, ELISA, Immunohistochemistry, Immuno Mass Spectroscopy and Surface Plasmon Resonance.  These assays provide the research community with information about the general effectiveness of an antibody in several different settings to determine its appropriateness for research needs.  The results (positive and negative) and associated SOPs from these assays are made publicly available on the Antibody Portal.  Information about the M-CRADAs can be found at the following website (click here).  For more information on collaborative opportunities can be found by contacting us at cancer.proteomics@mail.nih.gov.